MicroRNAs and Cancer Drug Resistance: over Two Thousand Characters in Search of a Role

Overview

Journal Cancer Drug Resist

Date 2022 May 18

PMID 35582590

Authors

Bruno Costa Gomes

Jose Rueff

Antonio Sebastiao Rodrigues

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs), a group of small regulatory noncoding RNAs, transformed our thinking on gene regulation. More than two thousand human miRNAs have been identified thus far. These bind imperfectly to the 3'-untranslated region of target mRNA and have been involved in several pathological conditions including cancer. In fact, major hallmarks of cancer, such as the cell cycle, cell proliferation, survival and invasion are modulated by miRNAs. Cancer drug resistance (CDR) has also been described as being modulated by miRNAs. CDR remains a burden for cancer therapy and patients' outcome, often resulting in more aggressive tumours that tend to metastasize to distant organs. In this review we discuss the role of miRNAs influencing drug metabolism and drug influx/efflux, two important mechanisms of CDR.

Citing Articles

Recent Advances in Novel Recombinant RNAs for Studying Post-transcriptional Gene Regulation in Drug Metabolism and Disposition.

Tu M, Yu A Curr Drug Metab. 2023; 24(3):175-189.

PMID: 37170982 PMC: 10825985. DOI: 10.2174/1389200224666230425232433.

miRNAs in Regulation of Tumor Microenvironment, Chemotherapy Resistance, Immunotherapy Modulation and miRNA Therapeutics in Cancer.

Kousar K, Ahmad T, Abduh M, Kanwal B, Shah S, Naseer F Int J Mol Sci. 2022; 23(22).

PMID: 36430305 PMC: 9699074. DOI: 10.3390/ijms232213822.

ABC Efflux Transporters and the Circuitry of miRNAs: Kinetics of Expression in Cancer Drug Resistance.

Gomes B, Honrado M, Armada A, Viveiros M, Rueff J, Rodrigues A Int J Mol Sci. 2020; 21(8).

PMID: 32340269 PMC: 7215654. DOI: 10.3390/ijms21082985.

References

Blackburn H, Ellsworth D, Shriver C, Ellsworth R . Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy. Cancer Causes Control. 2015; 26(3):319-32. DOI: 10.1007/s10552-014-0519-7. View

Bu Z, Ye M, Cheng Y, Wu W . Four polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene and lung cancer risk: a meta-analysis. Asian Pac J Cancer Prev. 2014; 15(14):5673-9. DOI: 10.7314/apjcp.2014.15.14.5673. View

Hao G, Ding Y, Wen H, Li X, Zhang W, Su H . Attenuation of deregulated miR-369-3p expression sensitizes non-small cell lung cancer cells to cisplatin via modulation of the nucleotide sugar transporter SLC35F5. Biochem Biophys Res Commun. 2017; 488(3):501-508. DOI: 10.1016/j.bbrc.2017.05.075. View

Gao M, Miao L, Liu M, Li C, Yu C, Yan H . miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1. Oncotarget. 2016; 7(37):59714-59726. PMC: 5312343. DOI: 10.18632/oncotarget.10845. View

Dluzen D, Lazarus P . MicroRNA regulation of the major drug-metabolizing enzymes and related transcription factors. Drug Metab Rev. 2015; 47(3):320-34. PMC: 6309899. DOI: 10.3109/03602532.2015.1076438. View

Yu X, Dhakal I, Beggs M, Edavana V, Williams S, Zhang X . Functional genetic variants in the 3'-untranslated region of sulfotransferase isoform 1A1 (SULT1A1) and their effect on enzymatic activity. Toxicol Sci. 2010; 118(2):391-403. PMC: 2984532. DOI: 10.1093/toxsci/kfq296. View

McLellan L, Wolf C . Glutathione and glutathione-dependent enzymes in cancer drug resistance. Drug Resist Updat. 2001; 2(3):153-164. DOI: 10.1054/drup.1999.0083. View

Mao M, Wu Z, Chen J . MicroRNA-187-5p suppresses cancer cell progression in non-small cell lung cancer (NSCLC) through down-regulation of CYP1B1. Biochem Biophys Res Commun. 2016; 478(2):649-55. DOI: 10.1016/j.bbrc.2016.08.001. View

Hill C, Jamieson D, Thomas H, Brown C, Boddy A, Veal G . Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo. Biochem Pharmacol. 2012; 85(1):29-37. PMC: 3545186. DOI: 10.1016/j.bcp.2012.10.004. View

10.

Shukla U, Tumma N, Gratsch T, Dombkowski A, Novak R . Insights into insulin-mediated regulation of CYP2E1: miR-132/-212 targeting of CYP2E1 and role of phosphatidylinositol 3-kinase, Akt (protein kinase B), mammalian target of rapamycin signaling in regulating miR-132/-212 and miR-122/-181a expression.... Drug Metab Dispos. 2013; 41(10):1769-77. PMC: 3781375. DOI: 10.1124/dmd.113.052860. View

11.

Dean M, Rzhetsky A, Allikmets R . The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001; 11(7):1156-66. DOI: 10.1101/gr.184901. View

12.

Moriya Y, Nohata N, Kinoshita T, Mutallip M, Okamoto T, Yoshida S . Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma. J Hum Genet. 2011; 57(1):38-45. DOI: 10.1038/jhg.2011.126. View

13.

Li X, Pan Y, Seigel G, Hu Z, Huang M, Yu A . Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem Pharmacol. 2011; 81(6):783-92. PMC: 3042498. DOI: 10.1016/j.bcp.2010.12.018. View

14.

Mercer K, Apostolov E, Gamboa da Costa G, Yu X, Lang P, Roberts D . Expression of sulfotransferase isoform 1A1 (SULT1A1) in breast cancer cells significantly increases 4-hydroxytamoxifen-induced apoptosis. Int J Mol Epidemiol Genet. 2011; 1(2):92-103. PMC: 3076764. View

15.

Lee R, Ambros V . An extensive class of small RNAs in Caenorhabditis elegans. Science. 2001; 294(5543):862-4. DOI: 10.1126/science.1065329. View

16.

Pan Y, Zhou A, Hu Z, Yu A . Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos. 2013; 41(10):1744-51. PMC: 3781368. DOI: 10.1124/dmd.113.052092. View

17.

Vaidyanathan A, Sawers L, Gannon A, Chakravarty P, Scott A, Bray S . ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer. 2016; 115(4):431-41. PMC: 4985349. DOI: 10.1038/bjc.2016.203. View

18.

Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J . Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int J Cancer. 2003; 108(1):146-51. DOI: 10.1002/ijc.11528. View

19.

Guo J, Jin D, Wu Y, Yang L, Du J, Gong K . The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells. EBioMedicine. 2018; 35:204-221. PMC: 6419862. DOI: 10.1016/j.ebiom.2018.08.001. View

20.

Wang H, Zhan M, Xu S, Chen W, Long M, Shi Y . miR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer. Cell Death Dis. 2017; 8(5):e2770. PMC: 5520703. DOI: 10.1038/cddis.2017.178. View